Japan Genomic Medicine Market to Reach US$ 5.1 Billion by 2032 at 13.9% CAGR; Strong Government Support and Oncology Applications Drive Growth

The Japan Genomic Medicine Market was valued at US$ 1.8 billion in 2024 and is expected to reach US$ 5.1 billion by 2032, growing at a CAGR of 13.9% during the forecast period 2025-2032. Market growth is driven by strong government support for precision medicine programs, increasing integration of genomics into routine clinical practice, and rising investments in sequencing infrastructure and life sciences research across Japan.

Genomic medicine in Japan involves the use of advanced DNA- and RNA-based technologies such as next-generation sequencing (NGS), PCR, and bioinformatics platforms to support personalized diagnosis and targeted treatment. The market is strongly supported by applications in oncology, rare and inherited diseases, and pharmacogenomics, aligned with Japan's aging population and the growing prevalence of chronic conditions. Increasing adoption of cancer genome profiling, advancements in AI-enabled genomic data analysis, and collaboration between hospitals, research institutions, and biotechnology companies are further strengthening the long-term growth outlook of the Japan genomic medicine market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/japan-genomic-medicine-market?sai-v

The genomic medicine market refers to the global industry focused on applying genomic information and technologies to enable personalized disease prevention, diagnosis, and treatment.

Key Developments
✅ January 2026: Japanese hospitals expanded the use of AI-assisted genomic interpretation platforms to support clinical decision-making in oncology and rare disease diagnosis, improving turnaround time and treatment precision.

✅ December 2025: The Ministry of Health, Labour and Welfare supported wider implementation of cancer genomic profiling tests under Japan's national insurance framework, increasing patient access to precision medicine.

✅ November 2025: Takeda Pharmaceutical advanced multiple genome-guided therapy programs in Japan, focusing on rare inherited disorders and pharmacogenomics-based treatment selection.

✅ October 2025: Daiichi Sankyo expanded large-scale tumor genome sequencing initiatives across Japanese cancer centers to enhance personalized oncology treatment pathways.

✅ September 2025: Sysmex Corporation launched integrated genomic diagnostic workflows in Japan, combining sequencing, bioinformatics, and clinical reporting for early cancer detection.

✅ August 2025: Fujifilm Group introduced advanced gene-expression and biomarker analysis solutions in Japan to support immunotherapy response prediction and personalized treatment planning.

Mergers & Strategic Moves
✅ December 2025: Japanese pharmaceutical companies increased strategic collaborations with domestic genomics startups to accelerate development of precision diagnostics and companion diagnostic solutions.

✅ October 2025: Major diagnostics firms in Japan formed long-term partnerships with university hospitals to deploy genomic medicine platforms for population-scale cancer screening programs.

✅ September 2025: Genomics-focused research institutes and biotech companies in Japan entered joint development agreements to advance next-generation sequencing technologies for clinical use.

Key Players
RIKEN GENESIS CO., LTD. | Chugai Pharmaceutical Co., Ltd. | Illumina, Inc. | QIAGEN | Agilent Technologies, Inc. | Thermo Fisher Scientific Inc. | Oxford Nanopore Technologies plc. | Takara Bio Inc. | Eurofins Scientific

Key Highlights
Illumina, Inc. - Holds 24.6% share, driven by leadership in next-generation sequencing platforms, strong adoption in clinical genomics, and widespread use in research institutions across Japan.

Thermo Fisher Scientific Inc. - Holds 18.9% share, supported by comprehensive genomics workflows, strong presence in clinical research, and advanced sequencing and sample preparation technologies.

QIAGEN - Holds 13.7% share, benefiting from expertise in sample preparation, molecular diagnostics, and strong integration with sequencing and PCR-based genomic workflows.

Agilent Technologies, Inc. - Holds 11.4% share, driven by high-quality genomic reagents, microarrays, and target enrichment solutions widely used in precision medicine research.

Chugai Pharmaceutical Co., Ltd. - Holds 9.2% share, supported by strong investments in precision oncology, genomic drug discovery, and close collaboration with Japanese research institutions.

Takara Bio Inc. - Holds 8.1% share, leveraging domestic manufacturing strength, genomic reagents, and growing adoption in academic and clinical laboratories across Japan.

Oxford Nanopore Technologies plc. - Holds 6.0% share, driven by portable and long-read sequencing platforms gaining traction in clinical research and infectious disease genomics.

Eurofins Scientific - Holds 4.5% share, providing genomic testing, bioinformatics, and contract research services for pharmaceutical and biotechnology companies.

RIKEN GENESIS CO., LTD. - Holds 3.6% share, focused on population genomics, clinical sequencing services, and national-level precision medicine initiatives in Japan.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=japan-genomic-medicine-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rising burden of cancer and rare genetic disorders in Japan increasing demand for precision diagnostics and targeted therapies.

- Strong government support for genomic medicine through national genome projects, cancer genome profiling programs, and public healthcare integration.

- Growing adoption of next-generation sequencing and companion diagnostics in oncology and rare disease management.

- Expansion of personalized medicine approaches to improve treatment outcomes and reduce adverse drug reactions.

- Increasing collaboration between academic institutions, hospitals, and biotechnology companies to advance genomic research and clinical application.

Industry Developments
- Expansion of national genomic databases and biobanks to support large-scale genomic research and population-level studies.

- Increased integration of genomic testing into routine clinical practice, particularly in oncology and inherited disease diagnosis.

- Strategic partnerships between Japanese pharmaceutical companies and global biotech firms to accelerate genomic drug development.

- Advancements in bioinformatics, AI-based genomic data analysis, and clinical decision-support tools.

- Investment in domestic manufacturing and development of genomic testing kits and sequencing technologies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/japan-genomic-medicine-market?sai-v

Key Segments

By Product Type
Kits and reagents represent the largest share of the market, driven by recurring demand, high testing volumes, and continuous consumption across research and clinical laboratories. Instruments and equipment hold a significant share, supported by ongoing investments in advanced genomic and molecular diagnostic platforms. Other products contribute steadily through specialized consumables and supporting tools.

By Technology
Next-generation sequencing dominates the market, driven by its high throughput, accuracy, and expanding use in precision medicine and large-scale genomic studies. Polymerase chain reaction remains a core technology, supported by its reliability, cost-effectiveness, and widespread adoption in routine diagnostics. Microarray technology holds a notable share, particularly in gene expression and genotyping studies. Gene editing technologies are witnessing rapid growth, driven by advancements in CRISPR-based tools and therapeutic research. Bioinformatics is expanding steadily, supported by increasing data complexity and the need for advanced data analysis and interpretation. Other technologies support niche and emerging applications.

By Application
Oncology represents the leading application segment, driven by rising cancer incidence and strong demand for personalized medicine. Cardiology applications are growing steadily, supported by increasing focus on genetic risk assessment and preventive care. Paediatrics contributes notably through genetic screening and rare disease diagnostics. Endocrinology applications are supported by growing prevalence of metabolic and hormonal disorders. Infectious diseases hold a substantial share, driven by molecular testing and surveillance needs. Other applications contribute through diverse clinical and research use cases.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.